Angioedema
Oct 25, 2007
Dyax's Loss Widens As Costs Rise to Develop Rare Blood Disease Treatment, Revenue Declines
Drug developer Dyax Corp. said Wednesday its third-quarter loss widened on higher costs for its DX-88 hereditary angioedema treatment candidate and lower revenue. via Canadian Business Magazine
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Angioedema. Please comment. | Jul 17 | Peter | 2 |
| New to all this (from Apr '06) | Apr '06 | Anita | 1 |
Most Popular
